Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-453-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.97 million
Profitability
Miscellaneous
Employees194
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?
Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Arena Pharmaceuticals' earnings last quarter?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.06. The biopharmaceutical company had revenue of $8.65 million for the quarter, compared to analysts' expectations of $3.33 million. Arena Pharmaceuticals had a negative net margin of 163.60% and a negative return on equity of 24.36%. The firm's revenue was down 43.7% on a year-over-year basis. During the same period last year, the company posted ($0.35) EPS. View Arena Pharmaceuticals' Earnings History.
When is Arena Pharmaceuticals' next earnings date?
What price target have analysts set for ARNA?
5 brokerages have issued 12 month target prices for Arena Pharmaceuticals' shares. Their predictions range from $55.00 to $77.00. On average, they expect Arena Pharmaceuticals' share price to reach $64.80 in the next year. This suggests a possible upside of 38.9% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.
What is the consensus analysts' recommendation for Arena Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.
What are Wall Street analysts saying about Arena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $62 price target. Arena today (2/26) reported 4Q18 earnings, with all programs remaining on track, including pivotal Ph3 initiations in 2019 for etrasimod in ulcerative colitis (UC) and Crohn’s. We are adjusting our estimates to reflect increasing investment in R&D as the pipeline advances. Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim." (2/26/2019)
- 2. According to Zacks Investment Research, "Arena Pharmaceuticals reported is focused on developing its three pipeline candidates – ralinepag, etrasimod and olorinab. The company has signed an agreement with United Therapeutics to divest Ralinepag for $1.2 billion. The company’s collaboration agreements provide milestone payments and steady revenue stream from royalties on Belviq sales. Meanwhile, the company’s decision to sell its manufacturing operations to focus on pipeline is prudent, in our view. However, all of Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry in the past six months." (1/15/2019)
Has Arena Pharmaceuticals been receiving favorable news coverage?
News articles about ARNA stock have trended somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Arena Pharmaceuticals' key competitors?
Some companies that are related to Arena Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Marina Biotech (MRNA), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS) and Nektar Therapeutics (NKTR).
What other stocks do shareholders of Arena Pharmaceuticals own?
Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the folowing people:
- Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
- Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
- Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Vincent E. Aurentz, Chief Bus. Officer & Exec. VP (Age 51)
- Dr. Preston S. Klassen, Chief Medical Officer and Exec. VP of R&D (Age 50)
Who are Arena Pharmaceuticals' major shareholders?
Arena Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.47%), Bailard Inc. (0.14%), Chartwell Investment Partners LLC (0.11%), Virginia Retirement Systems ET AL (0.04%), Los Angeles Capital Management & Equity Research Inc. (0.04%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Preston Klassen, Steven W Spector and Tina Susan Nova. View Institutional Ownership Trends for Arena Pharmaceuticals.
Which major investors are selling Arena Pharmaceuticals stock?
ARNA stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Meeder Asset Management Inc. and Virginia Retirement Systems ET AL. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Preston Klassen, Steven W Spector and Tina Susan Nova. View Insider Buying and Selling for Arena Pharmaceuticals.
Which major investors are buying Arena Pharmaceuticals stock?
ARNA stock was acquired by a variety of institutional investors in the last quarter, including Los Angeles Capital Management & Equity Research Inc., Bailard Inc., BNP Paribas Arbitrage SA, Strs Ohio and Chartwell Investment Partners LLC. View Insider Buying and Selling for Arena Pharmaceuticals.
How do I buy shares of Arena Pharmaceuticals?
Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arena Pharmaceuticals' stock price today?
One share of ARNA stock can currently be purchased for approximately $46.65.
How big of a company is Arena Pharmaceuticals?
Arena Pharmaceuticals has a market capitalization of $2.31 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.
What is Arena Pharmaceuticals' official website?
How can I contact Arena Pharmaceuticals?
Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]
MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
